Therapeutic Classification: lipid-lowering agents
Pharmacologic Classification: hmg coa reductase inhibitors
REMS
Absorption: 98% absorbed after oral administration but undergoes extensive first-pass hepatic metabolism resulting in 24% bioavailability.
Distribution: Well distributed to tissues.
Protein Binding: >98%.
Half-Life: 1.2 hr.
Contraindicated in:
Use Cautiously in:
CV: chest pain, peripheral edema
Derm: photosensitivity, pruritus, rash
EENT: pharyngitis, rhinitis
Endo: hyperglycemia
GI: ↑liver enzymes, abdominal pain/cramps, constipation, dyspepsia, flatulence, nausea, vomiting
MS: arthritis, back pain, immune-mediated necrotizing myopathy, myopathy, RHABDOMYOLYSIS
Neuro: amnesia, confusion, dizziness, fatigue, headache, insomnia, memory loss
Resp: bronchitis, cough, sinusitis
Drug-drug:
Lab Test Considerations: